Association of the p53 codon 72 polymorphism with breast cancer in central part of Iran

Hojjat Rouhi Boroujeni¹, Mehrdad Karimi²*, Saadat Moshkelani³ and Pouya Parsaei³

¹Department of Pharmacology, Shahrekord University of Medical Sciences, Shahrekord, Iran.
²Department of Surgery, Shahrekord University of Medical Sciences, Shahrekord, Iran.
³Young Researchers Club, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran.

Key words: Breast cancer, protein 53 (p53), polymorphism, codon 72.

INTRODUCTION

Breast cancer is the most frequently encountered cancer in women throughout the world. Epidemiologic studies have suggested a number of risk factors, including genetic and environmental ones. The protein 53 (p53) tumor suppressor gene occupies a central role in mediating cellular responses to DNA damage. Its activation results in either growth arrest in the G1 phase of the cell cycle or in apoptosis. The p53 gene contains a variety of polymorphisms and mutations (Zur Hausen, 2002; Aoki et al., 2009). Mutations in the p53 gene are associated with more than 50% of human cancers, and 90% of them affect p53-DNA interactions, and result in a partial or complete loss of transactivation functions (Zubov et al., 2009).

The p53 tumor suppressor gene, located on chromosome 17p13, is one of the most commonly mutated genes in all types of human cancer (He et al., 2011; Chen et al., 2008). The p53 tumor suppressor gene is frequently mutated in many forms of human carcinomas. A common polymorphism occurs at codon 72 of exon 4, with two alleles encoding either arginine (CGC) or proline (CCC). This p53 polymorphism is reportedly associated with cancer susceptibility. The distribution of the three genotypes (Arg/Arg, Arg/Pro and Pro/Pro) depends largely on the ethnic composition of the studied population (Özbey et al., 2011). Recent studies showed the relation between p53 gene polymorphism with cancer of the stomach (Takeda et al., 2000), lung (Özbey et al., 2011), breast (Pich et al., 2000), ovary...
(Agorastos et al., 2004) and cervix (Jiang et al., 2010) among others in different parts of the world. In the present study, we examined the relation between the codon 72 polymorphism in p53 and the risk for breast tumorigenesis in Iranian patients.

MATERIALS AND METHODS

Sample collection and DNA extraction

Genomic DNA was purified from blood samples of 135 cases of breast cancer and 150 controls by DNA extraction kit according to the manufacturer’s instructions. Samples were recruited from different hospitals of Isfahan (central part of Iran) during the period from February 2010 - October 2011. The isolated DNA was quantified by the agarose gel.

Primer, polymerase chain reaction (PCR) assay and restriction fragment length polymorphism (RFLP) analysis

PCR amplification was performed with two sets of primers: the outer oligonucleotide primers (forward: 5'-GCT CTT TTC ACC CAT CTA CAG -3'; reverse: 5'-TGA AGT CTC ATG GAA GCC AGC-3') and the inner oligonucleotide primers (forward: 5'-TCC CCC TTG C TG TCC CAA- 3'; reverse: 5'-CGT GCA AGT CAC AGA CT-3') (Doosti et al., 2011).

The target sequence was amplified in a 50 μL reaction volume containing of genomic DNA, 0.2 mM dNTPs, 1X Taq buffer, 2 mM MgCl₂, 100 ng of each primer, and 1 unit of Taq DNA polymerase (Fermentas, Germany). The first round of PCR was carried out by applying a step-up program as follows: initial denaturation for 5 min at 94°C, followed by 30 cycles of 94°C for 1 min, 58°C for 1 min, and 72°C for 1 min, with a final extension for 5 min at 72°C. Two to 5 μL from the first round amplicon was used as a template for the second round PCR with the identical PCR program by inner oligonucleotide primers.

The BstU I restriction enzyme cuts within the sequence corresponding to the arginine codon (CGG) at position 72 to generate two visible fragments of 160 and 119 bp, leaving the proline allele uncut. A 20-μL of PCR product was digested overnight at 37°C in a 25 μL reaction volume containing 5 units of BstU I (Fermentas, Germany). After overnight digestion, the fragments were separated by electrophoresis on a 2% agarose gel and stained with ethidium bromide. Logistic regression analyses were used to adjust for possible confounding variables, and data were evaluated using the Pearson $X^2$ tests.

RESULTS

Genotyping of the p53 codon 72 polymorphism was successful in 135 of 142 (95.07%) breast cancer cases and 150 of 158 (94.93 %) controls. Codon 72 arginine and proline alleles were investigated by PCR-based digestion analysis. The recognition site (CGCG) of the restriction enzyme was present only in the arginine-encoding allele. Thus, the proline allele is identified by the presence of a single fragment of 279 bp, and the arginine allele by two fragments of 160 and 119 bp, respectively. Heterozygous samples displayed all three fragments (Figure 1).

The frequency of the two alleles in breast cancer patients was compared with the frequency in the healthy control subjects. A significant difference in the genotype distribution was observed between the controls and patients with breast cancer. The distribution of the Arg/Arg, Arg/Pro and Pro/Pro genotypes in the control group was 36, 93 and 21 respectively. Allele frequencies in the control group were 0.55 for the Arg allele and 0.45 for the Pro allele. Among the patients, the frequencies of the Arg and Pro allele were 0.57 and 0.43 respectively. The corresponding distribution of the Arg/Arg, Arg/Pro and Pro/Pro genotypes in the patients was 27, 102 and 6, respectively (Table 1).

Our results indicate that individual heterozygous for the Arg allele has a higher risk of developing breast cancer than homozygotes and proline- homozygotes. A comparison of the genotype frequencies between breast cancer patients and normal controls confirmed the accumulation of Arg/Pro genotype in these patients ($P<0.01$).
DISCUSSION

Although several studies have attempted to establish an eventual association between the polymorphism at codon 72 and human carcinogenesis, the issue is still a matter of controversy. Interestingly, a polymorphism has been demonstrated at codon 72, where the proline is frequently replaced by an arginine. Both forms are morphologically wild-type and do not differ in their ability to bind to DNA in a sequence-specific manner. However, there are a number of differences between these p53 variants in their abilities to bind components of the transcriptional machinery, to activate transcription, to induce apoptosis, and to repress the transformation of primary cells (Thomas et al., 1999). It has been shown that the codon 72 polymorphism (Arg-Pro polymorphism) of the common tumor suppressor p53 gene contributes to susceptibility to breast cancer. The Arg/Pro heterozygous genotype occurred more frequently in this cancer. The prevalence of the Arg/Pro genotype in breast cancer was higher than that of other genotypes.

In this study, we examined the prevalence of p53 codon 72 polymorphisms in a number of Iranian groups of breast cancer patients and controls. The prevalence of the Arg/Pro genotype in carcinoma cases was statistically different from that of the controls (75.55% versus 62%). Several studies have examined the role of the codon 72 polymorphism in mutation of the p53 gene in cancer. Langerod et al. (2002) identified p53 mutations more commonly in breast cancer from Arg/Arg homozygotes (28.5%), than among Arg/Pro heterozygotes (21%) or Pro/Pro homozygotes (4%). However, no difference in p53 mutation frequency among codon 72 genotypes has been reported in colorectal or bladder cancer (Furihata et al., 2002). Several studies have also suggested that the codon 72 Arg allele is preferentially mutated and retained in Arg/Pro heterozygotes (Tada et al., 2001). These authors have suggested that the codon 72 Arg containing mutants may have a selective growth advantage influencing the ratio of Arg and Pro containing mutants in tumors. Another study also observed the prevalence of homozygosity for the p53 Arg allele and a strong association between the Arg/Arg genotype in breast cancer patients (Buyru et al., 2003). Recently, higher number of arg allele was observed in breast cancer patients when compared to the controls suggesting that the arg allele may be associated with predisposing Indian women to breast cancer (Suresh et al., 2011).

CONCLUSIONS

In this study, the heterozygosity for Arg/Pro of p53 codon 72 was associated with breast cancer. Heterozygosity for Arg/Pro of p53 Arg72Pro is potentially one of the genetic risk factors for breast cancer in Iranian population. Therefore, the p53 Arg72Pro polymorphism may be used as a stratification marker in screening individuals at a high risk of breast cancer. In summary, the findings of the present study indicate that the p53 codon 72 polymorphism may be a genetic predisposing factor for breast adenocarcinomas, and p53 Arg 72 protein may be correlated with possible increased risk of this kind of cancers in central part of Iran.

ACKNOWLEDGEMENT

The authors are grateful to the competitors of Biotechnology Research Center of Islamic Azad University, Shahrekord Branch, for valuable discussion and useful suggestions of this work.

REFERENCES


Table 1. Genotype and allele frequencies of p53 in patients with breast cancer and controls.

<table>
<thead>
<tr>
<th>Codon 72 genotypes</th>
<th>Breast cancer (n = 95.07%)</th>
<th>Controls (n = 94.93%)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arg/Arg</td>
<td>27 (20)</td>
<td>36 (24)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Arg/Pro</td>
<td>102 (75.55)</td>
<td>93 (62)</td>
<td>&lt;0.02</td>
</tr>
<tr>
<td>Pro/Pro</td>
<td>6 (4.45)</td>
<td>21 (14)</td>
<td>&gt;0.005</td>
</tr>
<tr>
<td>Arg Alleles</td>
<td>57</td>
<td>55</td>
<td>&gt;0.10</td>
</tr>
<tr>
<td>Pro Alleles</td>
<td>43</td>
<td>45</td>
<td>&lt;0.05</td>
</tr>
</tbody>
</table>
Cancer Res. Treat. In press.


